Back to Bank of New York Mellon Corp Bank of New York Mellon Corp

CHRSCHRS
28 quarters

Position history for Bank of New York Mellon CorpBank of New York Mellon Corp's holdings in COHERUS ONCOLOGY INC

Yes. Bank of New York Mellon holds 319,687 shares of CHRS (Coherus Oncology), worth $447,563, as of its Q2 2026 13F filing. It increased the position by 34,654 shares (+12.2%) from Q1 2026. Bank of New York Mellon has held CHRS in every 13F on record since Q3 2019, 28 quarterly filings.

Current Value

$447,563

Current Shares

319,687

Total Value Change

-$5.1M

Total Shares Change

+46,948

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
319,687
+12.2%
$447,5630.0%$1.40
27
2026-Q1
Decreased
285,033
-2.0%
$481,7060.0%$1.69
0
2025-Q4
Decreased
290,863
-22.8%
$413,0250.0%$1.42
0
2025-Q3
Decreased
376,685
-3.5%
$617,7630.0%$1.64
0
2025-Q2
Increased
390,313
+0.3%
$285,4350.0%$0.73
23
2025-Q1
Decreased
389,121
-0.5%
$314,0200.0%$0.81
0
2024-Q4
Increased
391,002
+26.6%
$539,5820.0%$1.38
30
2024-Q3
Decreased
308,780
-20.7%
$321,1310.0%$1.04
0
2024-Q2
Increased
389,225
+26.0%
$673,3590.0%$1.73
30
2024-Q1
Decreased
309,003
-12.8%
$738,5170.0%$2.39
0
2023-Q4
Decreased
354,271
-10.4%
$1.2M0.0%$3.33
0
2023-Q3
Decreased
395,527
-33.0%
$1.5M0.0%$3.74
0
2023-Q2
Increased
590,048
+5.2%
$2.5M0.0%$4.27
28
2023-Q1
Decreased
560,900
-3.2%
$3.8M0.0%$6.84
0
2022-Q4
Decreased
579,408
-7.1%
$4.6M0.0%$7.92
0
2022-Q3
Increased
623,891
+7.7%
$6M0.0%$9.61
29
2022-Q2
Decreased
579,311
-3.0%
$4.2M0.0%$7.24
0
2022-Q1
Decreased
597,045
-15.8%
$7.7M0.0%$12.91
0
2021-Q4
Decreased
709,284
-12.9%
$11.3M0.0%$15.96
0
2021-Q3
Increased
814,371
+2.9%
$13.1M0.0%$16.07
29
2021-Q2
Decreased
791,099
-4.6%
$10.9M0.0%$13.83
0
2021-Q1
Increased
829,625
+0.7%
$12.1M0.0%$14.61
28
2020-Q4
Increased
824,236
+16.1%
$14.3M0.0%$17.38
32
2020-Q3
Increased
710,166
+0.7%
$13M0.0%$18.34
28
2020-Q2
Increased
705,156
+154.6%
$12.6M0.0%$17.86
45
2020-Q1
Decreased
276,946
-0.5%
$4.5M0.0%$16.22
0
2019-Q4
Increased
278,371
+2.1%
$5M0.0%$18.01
27
2019-Q3
First report
272,739
-
$5.5M0.0%$20.26
0

Other major holders of CHRS: Temasek Holdings (Private) Ltd, WELLINGTON MANAGEMENT GROUP LLP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used